Stockreport
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced 36 abstracts across its immunology and inflammation portfolio and pipeline will be presented at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting being held February 27 to March 2 in Philadelphia, Pennsylvania. Highlights include the first presentations from the novel Phase 3 allergen-specific programs demonstrating the potential of a first-in-class approach to addressing burdensome ocular symptoms in adults with cat an
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.[MarketBeat]
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.[MarketBeat]
- Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=REGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall[MarketBeat]
- A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance][Yahoo! Finance]
- More
REGN
SEC Filings
SEC Filings
- 2/9/26 - Form 144
- 2/9/26 - Form 144
- 2/6/26 - Form 13F-HR
- REGN's page on the SEC website
- More